News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Genzyme Corporation (GENZ)’s Lemtrada Recommended For Reimbursement On NHS By National Institute for Clinical Excellence (NICE)


5/28/2014 9:12:39 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY), announced today that the National Institute for Health and Care Excellence (NICE) issued final guidance recommending that Lemtrada™ (alemtuzumab) be reimbursed on the NHS, for treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease defined by clinical or imaging features. A Final Appraisal Determination (FAD) issued earlier this year concluded Lemtrada is a cost-effective use of NHS resources for MS treatment, and formed the basis of the final guidance for reimbursement.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES